title: ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
authors: Service de dermatologie, hôpitaux de Brabois, 6, rue du Morvan, 54511 Vandoeuvre-Lès-Nancy, France. jl.schmutz@chu-nancy.fr
authors: J-L
authors: JL
authors: Schmutz
authors: P
authors: P
authors: Trechot
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015984:Causality; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D015994:Incidence; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000139:chemically induced* / Q000453:epidemiology; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept